03:34 PM EST - Oncolytics Biotech Inc. : announced today that it has completed enrollment in the first, 80 patient stage of its Phase III clinical trial examining REOLYSIN® in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018). Oncolytics Biotech Inc.
shares T.ONC are trading up $0.14 at $4.35.
